THERAPEUTIC USE OF SARS-COV-2 MRNA DOMAIN VACCINES

Smart overview of the Invention

Coronaviruses, particularly the β-coronaviruses, are known for causing respiratory infections in humans. The emergence of SARS-CoV-2 has led to a global pandemic, highlighting the urgent need for effective vaccines. The described mRNA vaccines encode specific domains of the SARS-CoV-2 virus, aiming to generate strong immune responses against the virus and reduce infection severity.

Composition and Mechanism

The mRNA vaccines focus on encoding the spike (S) protein's key neutralizing domains, specifically the receptor binding domain (RBD) and N-terminal domain (NTD). These components are crucial for viral entry into host cells and are targeted to elicit robust antibody responses. By concentrating on specific subunits, the vaccines aim to minimize unwanted immune reactions while maximizing protection against SARS-CoV-2.

Therapeutic Dosage and Administration

Various therapeutic doses of the mRNA compositions are proposed, ranging from 5 μg to 100 μg. The recommended administration method is intramuscularly, often into the deltoid muscle. In some cases, a two-dose regimen is suggested, with the second dose administered at least 28 days after the first.

Formulation Details

The vaccine formulations include lipid nanoparticles to facilitate mRNA delivery. Key components may include ionizable amino lipids, neutral lipids, sterols, and PEG-modified lipids in specific ratios. Additionally, formulations may contain buffers such as Tris to maintain pH balance and stability.

Target Population and Immune Response

The vaccines are intended for a broad range of individuals, including those aged 18 and older, particularly targeting immunocompromised patients or those with chronic health conditions. The goal is to induce high levels of neutralizing antibodies against various SARS-CoV-2 variants, contributing to enhanced public health outcomes during ongoing pandemic challenges.